ArticleInternational journal of surgery case reports2026
Post-TEVAR type IA endoleak caused hemoptysis in a case of mid-thoracic aortic saccular aneurysm.
Article in International journal of surgery case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Aortobronchial fistula (ABF) is a rare complication of descending thoracic aortic pseudoaneurysm and massive hemoptysis. Computed tomography angiography (CTA) is the best modality for diagnosis. Urgent treatment is required for this condition. Case presentation: A 62-year-old man with a history of smoking and 2 years of intermittent hemoptysis was diagnosed with a descending thoracic aortic pseudoaneurysm with a fistula to the bronchi. Despite the initial thoracic endovascular aortic repair (TEVAR), hemoptysis persisted, and clinical evaluations showed a proximal type IA endoleak to the left lung hilum. A carotid-subclavian bypass (CSB) was done to secure the upper limb and vertebral circulation, followed by the deployment of two overlapping stent grafts extending from Zone 2 to the supraceliac region. The patient recovered well, with normal CTA findings at the 1-month follow-up. Clinical discussion: CTA is necessary for diagnosis. TEVAR is the first-line treatment for ABF from a thoracic aortic aneurysm, controlling the bleeding rapidly. Recurrent hemoptysis following TEVAR indicates a proximal type IA endoleak, which requires further intervention. Evidence and guidelines suggest left subclavian artery (LSA) revascularization and careful coverage length to reduce the risk of spinal cord ischemia, with hybrid or staged approaches improving seal durability and reducing recurrence. Because of the complex nature of ABF management, a multidisciplinary team is important for durable outcomes. Conclusion: TEVAR is an effective therapy for ABF. An endoleak is a complication that demands securing proximal and distal landing zones. CSB with extended TEVAR led to recovery, showing the importance of multidisciplinary planning, LSA revascularization, and careful follow-up for durable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.